Waiv Raises $33 Million in Series A Funding
Waiv, a Paris-based healthtech company specializing in AI-enabled precision medicine, has successfully raised $33 million in a Series A funding round. The financing was co-led by OTB Ventures and Alpha Intelligence Capital, with additional participation from investors such as Serene Data Ventures, Karista, and SistaFund.
Company Background
Waiv, which emerged as a spinout from the biotech firm Owkin, is focused on advancing precision oncology. The company employs artificial intelligence to enhance biomarker discovery and detection, improve outcome prediction, and assess treatment responses in cancer care. Co-founded by Meriem Sefta, who also serves as CEO, Waiv aims to transform cancer diagnostics by integrating AI into routine pathology and clinical workflows.
"Precision medicine only works when patients can be reliably matched to the therapies most likely to benefit them," said Meriem Sefta. "Our goal is to make accurate AI-enabled precision testing the global standard."
Strategic Investments and Partnerships
Waiv's platform analyzes digital pathology slides and various patient data to identify critical biological signals, aiding in more effective treatment decisions. The company collaborates with pharmaceutical giants such as AstraZeneca and MSD to develop AI-driven diagnostics and support drug development.
Use of Funds
The newly acquired capital will be utilized to expand Waiv's portfolio of clinical-grade tests and strengthen its partnerships with pharmaceutical companies. Furthermore, the funds will support the company's efforts to enter new international markets and integrate its diagnostic technologies into more healthcare settings globally.
Future Plans
Waiv plans to continue developing innovative AI oncology tests and enhance its technology's reach in laboratories and clinical environments worldwide. The company is dedicated to improving patient stratification and therapy selection, enabling faster and more accurate cancer treatment outcomes.
With this significant investment, Waiv is poised to set new benchmarks in the field of oncology, leveraging AI to bring about more precise and scalable cancer diagnostics.